AGA
- DateMay 21, 2024BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
Presenter
Speakers
Mayo ClinicUniversity of PittsburghStanford UniversityUniversity of WisconsinIndiana University Health Medical CenterMayo ClinicUniversity of FloridaAdventHealth Orlando - DateMay 20, 2024
Presenters
- DateMay 18, 2024BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…
Presenter
Speaker
- DateMay 21, 2024
Presenter
- DateMay 21, 2024SOCIETY: AGA
Moderators
Cedars-Sinai Medical CenterUniversity of Pennsylvania - DateMay 20, 2024
Presenter
- DateMay 20, 2024SOCIETY: AGA The AGA-FDA Town Hall provides health care professionals, clinical trial investigators, and other interested stakeholders an opportunity to hear directly from FDA representatives about the agency's thinking behind recent approvals, safety signals, guidance documents, and boxed warnings…
Moderators
Middleburg ConsultantsUniversity of Tennessee Health Science Center - DateMay 21, 2024BACKGROUND: Dietary therapy is an effective treatment for eosinophilic esophagitis (EoE), however, the influence of body mass index (BMI) on treatment response is unclear…
Presenter
Speakers
- DateMay 21, 2024INTRODUCTION: The novel hybrid GLP-1/GIP receptor agonist concept, with efficacy surpassing GLP-1 agonist medication, is promising for treatment of obesity. Nevertheless, its mechanism of action is not fully understood…
Presenter
Speakers
- DateMay 21, 2024INTRODUCTION: Roux-en-Y gastric bypass (RYGB) is an effective treatment for patients suffering from obesity and concomitant type 2 diabetes mellitus (T2DM). Nevertheless, less than 2% of eligible patients choose to undergo the surgery…
Presenter
Speakers
Brigham and Women's Hospital - DateMay 21, 2024INTRODUCTION: A diet low in FODMAPs (LFD) is only effective in 50-60% of patients with irritable bowel syndrome (IBS) and is restrictive, time-consuming, and carries the risk of nutritional deficiencies. Therefore, there is a need for novel dietary therapies for IBS…
Presenter
University of MichiganSpeakers
University of MichiganMichigan Medicine - DateMay 21, 2024INTRODUCTION: Body weight influences the GI response to meals. Studies have demonstrated post-prandial GI symptoms and dysfunction at the extremes of the BMI scale. More specifically, underweight individuals (BMI < 18…
Presenter
Massachusetts General Hospital - DateMay 21, 2024INTRODUCTION: A phenotype-tailored lifestyle intervention (PLI) has shown superior outcomes when compared to a standard lifestyle intervention (SLI) in a 12-week trial (PMID: 37007741). However, phenotype testing for obesity is time-consuming, expensive, and not widely accessible…
Presenter
Speakers
Mayo Foundation for Medical Education and Research - DateMay 21, 2024Previous studies showed that high FODMAP meals induced a higher frequency of transient lower esophageal sphincter relaxation and reflux symptoms in patients with overlapping IBS and GERD…
- DateMay 21, 2024SOCIETY: AGA
Moderators
Mayo Foundation for Medical Education and ResearchChildren's Los Angeles - DateMay 20, 2024BACKGROUND: In terms of temporality, constipation is categorized as either acute or chronic. When chronic constipation occurs without alarm features and secondary causes, it is labeled as functional chronic constipation (FCC, Rome IV)…